Epoch Investment Partners Inc. Sells 144,069 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Epoch Investment Partners Inc. reduced its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 41.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 202,267 shares of the specialty pharmaceutical company’s stock after selling 144,069 shares during the quarter. Epoch Investment Partners Inc. owned about 0.37% of Supernus Pharmaceuticals worth $6,899,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Fidelis Capital Partners LLC bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $33,000. EntryPoint Capital LLC bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $43,000. Quadrant Capital Group LLC boosted its position in shares of Supernus Pharmaceuticals by 1,117.6% during the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,330 shares in the last quarter. Covestor Ltd boosted its position in shares of Supernus Pharmaceuticals by 15.3% during the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 358 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Supernus Pharmaceuticals in the first quarter worth $129,000.

Supernus Pharmaceuticals Trading Up 0.2 %

Supernus Pharmaceuticals stock opened at $30.75 on Monday. The business’s fifty day simple moving average is $27.52 and its two-hundred day simple moving average is $29.28. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -106.03 and a beta of 0.91.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.